Pilsicainide hydrochloride is a new pynolizidine lidocaine derivative with
antiarrhythmic activity. It is the first pharmaceutical product introduced by Suntory
and was solely developed in Japan. The compound is reported to be highly effective in
the treatment of premature ventricular contraction. It has no anticholinergic or CNS
activity and is not as likely as other class 1C antiarrhythmics to have restricted
indications.
용도
Pilsicainide hydrochloride has been used as a sodium channel blocker:
to study its effects on electrophysiological parameters in guinea pig pulmonary vein preparation
to study its effects on Ca2+?release and arrhythmic events in Andersen-Tawil syndrome induced pluripotent stem cells (ATS-iPSC)-derived cardiomyocytes
to study its electrophysiological effects on the guinea pig atrium
